Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis by Bordoli, M R et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2011
Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor
2-dependent regulation of amphiregulin contributes to breast
tumorigenesis
Bordoli, M R; Stiehl, D P; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P;
Wenger, R H; Camenisch, G
Bordoli, M R; Stiehl, D P; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P; Wenger, R H; Camenisch, G
(2011). Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin
contributes to breast tumorigenesis. Oncogene, 30(5):548-560.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Bordoli, M R; Stiehl, D P; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P; Wenger, R H; Camenisch, G
(2011). Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin
contributes to breast tumorigenesis. Oncogene, 30(5):548-560.
Bordoli, M R; Stiehl, D P; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P; Wenger, R H; Camenisch, G
(2011). Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin
contributes to breast tumorigenesis. Oncogene, 30(5):548-560.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Bordoli, M R; Stiehl, D P; Borsig, L; Kristiansen, G; Hausladen, S; Schraml, P; Wenger, R H; Camenisch, G
(2011). Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin
contributes to breast tumorigenesis. Oncogene, 30(5):548-560.
Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor
2-dependent regulation of amphiregulin contributes to breast
tumorigenesis
Abstract
Hypoxia-elicited adaptations of tumor cells are essential for tumor growth and cancer progression.
Although ample evidence exists for a positive correlation between hypoxia-inducible factors (HIFs) and
tumor formation, metastasis and bad prognosis, the function of the HIF-α protein stability regulating
prolyl-4-hydroxylase domain enzyme PHD2 in carcinogenesis is less well understood. In this study, we
demonstrate that downregulation of PHD2 leads to increased tumor growth in a hormone-dependent
mammary carcinoma mouse model. Tissue microarray analysis of PHD2 protein expression in 281
clinical samples of human breast cancer showed significantly shorter survival times of patients with
low-level PHD2 tumors over a period of 10 years. An angiogenesis-related antibody array identified,
amongst others, amphiregulin to be increased in the absence of PHD2 and normalized after PHD2
reconstitution. Cultivation of endothelial cells in conditioned media derived from PHD2-downregulated
cells resulted in enhanced tube formation that was blocked by the addition of neutralizing
anti-amphiregulin antibodies. Functionally, amphiregulin was regulated on the transcriptional level
specifically by HIF-2 but not HIF-1. Our data suggest that PHD2/HIF-2/amphiregulin signaling has a
critical role in the regulation of breast tumor progression and propose PHD2 as a potential tumor
suppressor in breast cancer.Oncogene advance online publication, 20 September 2010;
doi:10.1038/onc.2010.433.
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Abstract 
Hypoxia-elicited adaptations of tumor cells are essential for tumor growth and cancer 
progression. While ample evidence exists for a positive correlation between hypoxia-
inducible factors (HIFs) and tumor formation, metastasis and bad prognosis, the function of 
the HIFα protein stability regulating prolyl-4-hydroxylase domain enzyme PHD2 in 
carcinogenesis is less well understood. Here, we demonstrate that downregulation of PHD2 
leads to increased tumor growth in a hormone-dependent mammary carcinoma mouse model. 
Tissue microarray analysis of PHD2 protein expression in 281 clinical samples of human 
breast cancer showed significantly shorter survival times of patients with low level PHD2 
tumors over a period of ten years. An angiogenesis-related antibody array identified, amongst 
others, amphiregulin to be increased in the absence of PHD2 and normalized after PHD2 
reconstitution. Cultivation of endothelial cells in conditioned media derived from PHD2 
downregulated cells resulted in enhanced tube formation that was blocked by addition of 
neutralizing anti-amphiregulin antibodies. Functionally, amphiregulin was regulated on the 
transcriptional level specifically by HIF-2 but not HIF-1. Our data suggest that PHD2/HIF-2/ 
amphiregulin signaling plays a critical role in regulating breast tumor progression and propose 
PHD2 as a potential tumor suppressor in breast cancer.  
 
Keywords: Amphiregulin, hypoxia-inducible factors, mammary carcinoma, prolyl-4-
hydroxylases, tumor vascularization.  
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Introduction 
Hypoxia is a characteristic feature of most solid tumors, contributes to the malignant 
phenotype and is associated with resistance to therapies and poor prognosis (Brown and 
Wilson, 2004; Pouysségur et al., 2006). Adaptive cellular responses to hypoxia are mainly 
mediated by heterodimeric hypoxia-inducible transcription factors (HIFs) and many HIF 
target genes are involved in cancer progression (Semenza, 2003; Wenger, 2002; Wenger et 
al., 2005). On the molecular level, HIFα protein stability and transactivation activity are 
regulated by oxygen-dependent hydroxylation of specific prolyl and asparaginyl residues. The 
HIF prolyl-4-hydroxylase domain proteins, PHD1, 2 and 3 are responsible for normoxic HIFα 
proteolysis. Prolyl-4-hydroxylation is necessary for the interaction with the von Hippel-
Lindau tumor suppressor protein (pVHL) that mediates HIFα degradation (Bruick and 
McKnight, 2001; Epstein et al., 2001; Ivan et al., 2002; Jaakkola et al., 2001; Maxwell et al., 
1999).  
Whereas HIFα overexpression is found in most human cancers (Zhong et al., 1999) and 
correlates with poor prognosis and resistance to treatment (Aebersold et al., 2001), the role of 
PHDs in tumor formation remains incompletely understood. Tumor suppressor functions have 
been proposed for PHD1 as well as PHD3, whereas both tumor promoting as well as 
suppressing effects have been reported for PHD2. Ectopic expression of PHD1 in colon 
carcinoma cells inhibited tumor growth and correlated with increased necrosis and decreased 
microvessel density in a mouse xenograft model (Erez et al., 2003). PHD3 was found to be 
downregulated in colorectal cancer cells and correlated with higher tumor grade and 
metastasis (Xue et al., 2009) and loss of PHD3 was associated with development of 
pheochromocytomas by acting downstream of c-Jun-mediated apoptosis (Lee et al., 2005). 
PHD2 has been reported to induce senescence in endometrial cancer cells by regulating HIF-
mediated signal transduction pathways (Kato et al., 2006). On the other hand, increased 
3 
Bordoli et al.  
expression levels of PHD2 have been shown to be associated with an aggressive phenotype in 
head and neck squamous cell carcinoma (Jokilehto et al., 2006). Overexpression of all three 
PHDs and the asparaginyl hydroxylase factor inhibiting HIF (FIH) correlated with tumor 
aggressiveness and higher rate of recurrence in pancreatic endocrine tumors (Couvelard et al., 
2008). In addition, a biphasic model for the relationship between PHD2 and tumor-forming 
potential has been suggested: small decreases of PHD2 led to malignant transformation of 
non-tumorigenic fibroblasts, whereas strongly decreased PHD2 levels did not (Lee et al., 
2008). In summary, the function of PHDs in cancer remains incompletely understood. Current 
data suggest that they can be functionally inactivated, genetically mutated and epigenetically 
downregulated in cancer and additional tissue-specific factors might impinge on PHD 
regulation.  
 Here we have studied the function of PHD2 in a mammary carcinoma model and 
demonstrate that PHD2 downregulation promotes tumor growth. In clinical samples, low 
PHD2 protein expression levels correlated significantly with shorter survival times of breast 
cancer patients. We confirmed PHD2-dependent VEGF and IL-8 modulation and identified 
amphiregulin to be induced by loss of PHD2 and normalized by PHD2 reconstitution, 
suggesting that amphiregulin contributes to breast cancer progression.  
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Results 
Increased tumor progression by PHD2 downregulation 
To investigate the role of PHD2 in tumor development, stable PHD2 knock-down clones and 
non-targeting control clones were generated in human breast carcinoma MCF-7 cells by 
shRNA interference. After selection, stable shPHD2 clones C1 and B1 were further analysed 
by RT-qPCR. Both clones showed efficient PHD2 mRNA downregulation under normoxic as 
well as prolonged hypoxic conditions (Figure 1a), whereas PHD1 and PHD3 mRNA levels 
were not significantly altered (data not shown). HIF-1α, HIF-2α and ARNT mRNA levels 
slightly varied under the conditions analyzed, but were not significantly affected by PHD2 
downregulation (Figure 1a). Parental MCF-7 and control shRNA transfected cells differed 
neither on the PHD2 mRNA (Figure 1a) or protein (Supplementary Figure S1) level, nor in 
proliferation or morphology (data not shown). Thus, both cell lines were subsequently used as 
controls. Immunoblot analysis confirmed efficient PHD2 knock-down in C1 and B1 clones 
also under prolonged hypoxic, i.e. PHD2 inducing conditions (Figure 1b). Stabilization of 
normoxic HIF-1α and increased hypoxic accumulation of HIF-2α protein was observed in 
PHD2-downregulated MCF-7 cells (Figure 1b and Figure 2b, respectively). In clone C9, the 
less efficient downregulation of PHD2 correlated with reduced normoxic HIF-1α stabilization 
when compared to the clones C1 and B1 (Figure 1b). Normoxic HIFα protein accumulation in 
shPHD2 cells is less pronounced than in hypoxic control cells, indicating that additional 
factors might contribute to the normoxic regulation of HIFα subunits in MCF-7 cells.  
To analyze the function of PHD2 in tumor formation in vivo, athymic nude mice were 
subcutaneously injected with parental and PHD2 knock-down MCF-7 cells. Because MCF-7 
proliferation is estrogen-dependent (Supplementary Figure S2), estrogen-releasing pellets 
were subcutaneously implanted into mice prior to the injection of MCF-7 cells. Tumor growth 
of PHD2-downregulated MCF-7 cells in vivo was significantly increased when compared to 
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control cells (Figure 1c, left panel). Importantly, differences in tumor growth were 
independent of unequal intrinsic proliferation potentials, since parental and shPHD2 MCF-7 
cells showed comparable growth rates and viability in vitro (Figure 1c, right panel). Tumor 
growth was analyzed over a time period of 60 days. Thereafter, sustained in vivo PHD2 
suppression was confirmed on the mRNA as well as on the protein levels (Supplementary 
Figure S3). Recently, it has been proposed that heterozygous endothelial Phd2 deficiency 
stabilizes tumor vasculature and inhibits metastasis (Mazzone et al., 2009). Although tumors 
in our model were wild-type for Phd2 in host-derived endothelial cells, we did not observe 
metastasis in mice subcutaneously injected with shPHD2 cells. Because MCF-7 are poorly 
invasive breast cancer cells, we injected these cells also intravenously but still detected no 
incidence of metastasis, even by RT-qPCR analysis of lung samples using human PHD2 
specific primers (data not shown).  
Analysis of PHD2 protein expression using a tissue micro array (TMA) of 281 human 
breast cancer patient samples showed predominantly a diffuse and fairly homogenous 
cytoplasmic immunoreactivity in invasive breast cancer cells and no membraneous staining. 
Low or very high PHD2 levels were observed in 82 and 199 cases, respectively (Figure 1d, 
left panel). Apart from a significant association of low PHD2 levels with a postmenopausal 
status, no other associations with clinico-pathological parameters were found (Supplementary 
Table 1). Univariate survival analysis by the Kaplan-Meier method showed significantly 
shorter survival times of patients with tumors having low PHD2 levels (ten years survival 
rates: 52% vs. 67%, p=0.026; Figure 1d, right panel). In a probatory multivariate Cox analysis 
(including tumor grades pT, pN, G) of estrogen receptor (ER) and PHD2, PHD2 failed to 
demonstrate independent prognostic significance (data not shown). To confirm the specificity 
of the anti-PHD2 antibody, parental MCF-7 and shPHD2 C1 cells were pelleted and 
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embedded in paraffin for immunohistochemical detection of PHD2 protein expression using 
the same conditions as for the TMA experiments (Supplementary Figure S4).  
 
Overexpression of PHD2 in shPHD2 cells suppresses tumor growth 
To exclude that shRNA off-target effects increased the tumor growth in shPHD2 MCF-7 
clones, we reconstituted the expression of PHD2 in the stable shPHD2 clone C1. Immunoblot 
analysis showed constitutively elevated PHD2 protein levels under normoxic as well as 
hypoxic conditions in the selected reconstituted clones #1 and #2 (Figure 2a). PHD2 
reconstitution also reduced normoxic HIF-1α protein levels and attenuated hypoxic HIF-2α 
accumulation (Figure 2b). Although PHD2 expression was higher in both reconstituted clones 
than in parental MCF-7 cells, no difference in in vitro proliferation rates and viability was 
observed (data not shown). Implantation of PHD2-reconstituted and parental MCF-7 cells into 
athymic nude mice resulted in tumors in 13.6% and 77.3% of all cases, respectively. In 
addition, the three successfully grown tumors of PHD2-reconstituted cells displayed a 
significantly decreased volume compared to tumors derived from parental MCF-7 cells 
(Figure 2c). Subsequent tumor tissue analysis confirmed increased PHD2 expression in 
reconstituted compared to parental cells, suggesting that PHD2 overexpression leads to 
suppression of tumor growth (Figure 2d).  
 
PHD2 suppression increases tumor angiogenesis and modulates secreted angiogenic factors 
Tumor vascularization of experimental tumors derived from parental and shPHD2 MCF-7 
cells was analysed by PECAM-1 immunostaining. Knock-down of PHD2 resulted in a more 
elaborated and denser vascular network (Figure 3a). Quantitative analysis revealed a 
significant increase in vessel density, area and diameter in shPHD2 compared to parental cells 
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(Figure 3b). Tumors derived from parental or shPHD2 MCF-7 cells showed no obvious 
morphological differences by hematoxylin/eosin staining (data not shown).  
To investigate a possible regulation of secreted angiogenic factors by altered PHD2 
levels, we incubated human angiogenesis arrays with conditioned media of parental, shPHD2 
or reconstituted PHD2 MCF-7 cells. To eliminate potential clonal differences between 
maternal and shPHD2 cell lines, we also used pools of lentivirally transduced shPHD2 MCF-
7 cells (Supplementary Figure S5). Compared to conditioned media of parental MCF-7 and 
reconstituted PHD2 cells, VEGF was increased in shPHD2 cells, suggesting activation of the 
HIF pathway (Supplementary Figure S6). In addition, IL-8 as well as amphiregulin were 
elevated in the absence of PHD2 while reduced in cells overexpressing PHD2 when compared 
to parental MCF-7 cells. Recently, IL-8 has been shown to be induced by PHD2 
downregulation in a HIF-independent but NF-κB-dependent manner (Chan et al., 2009), 
confirming the relevance of our experimental approach. However, amphiregulin induction by 
PHD2 downregulation has not been described previously.  
 Other pro-angiogenic factors abundantly secreted by MCF-7 cells include insulin-like 
growth factor binding protein 2 (IGFBP-2), matrix metallopeptidase 9 (MMP-9) and tissue 
inhibitor of metalloproteinase 1 (TIMP-1). However, secretion of these factors was 
independent of PHD2 (Supplementary Figure S6).  
 
PHD2 regulates amphiregulin-dependent tube formation in vitro 
To elaborate the PHD2-dependent function of amphiregulin in more detail, we performed 
tube formation assays in vitro. Incubation of HUVEC cells with supernatant of parental MCF-
7 cells resulted in moderate tube formation (Figure 3c). In contrast, following PHD2 
downregulation tube formation was significantly increased as determined by counting branch 
points and estimating total tube network length. Vice-versa, tube formation was markedly 
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decreased by shRNA-mediated downregulation of amphiregulin gene expression (Figure 3c), 
already following amphiregulin transcript level repression by only approx. 50% 
(Supplementary Figure S7). Importantly, stimulation of tube formation by supernatants of 
shPHD2 MCF-7 cells was significantly reduced by pre-incubation with a neutralizing anti-
amphiregulin antibody (Figure 3d), suggesting that the PHD2-mediated increase in tube 
formation was at least partly mediated by amphiregulin secretion.  
 
Amphiregulin transcription is regulated by PHD2 
Analysis of amphiregulin mRNA levels in MCF-7 cells by RT-qPCR demonstrated increased 
amphiregulin transcript levels following PHD2 suppression and reduced amphiregulin mRNA 
levels following PHD2 overexpression (Figure 4a). Transfection of a firefly luciferase 
reporter gene driven by the amphiregulin gene (AREG) promoter (pAREG) into parental, 
shPHD2 or reconstituted MCF-7 cells resulted in relative luciferase activities recapitulating 
the regulation of the endogenous amphiregulin transcript levels in these cell lines (Figure 4b). 
In contrast to the known hypoxia-inducible gene carbonic anhydrase 9 (CA9), amphiregulin 
mRNA levels were not induced under hypoxic conditions (Figure 4c), indicating that 
amphiregulin regulation might be independent of the prolyl-4-hydroxylase enzymatic function 
of PHD2. Moreover, pharmacologic inhibition of PHD hydroxylase function using the pan-
PHD inhibitor DMOG, did not induce amphiregulin expression whereas CA9 and PHD2 were 
increased as expected (Supplementary Figure S8).  
 To analyse the function of PHD2 on amphiregulin transcription in more detail, we 
transfected shPHD2 MCF-7 cells with pAREG reporter plasmids (depicted in Figure 4d) 
together with active (PHD2) or inactive hydroxylase mutant PHD2 (mtPHD2). All pAREG 
reporter plasmids were similarly responsive to PHD2 co-expression, irrespective of the 
presence of the putative HIF-binding site (HBS) and functional PHD2 hydroxylase activity 
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(Figure 4e, left panel). As expected, the HIF-dependent reporter plasmid pH3SVL (Wanner et 
al., 2000) responded to wild-type but not mutant PHD2. Hypoxic exposure only marginally 
induced pAREG reporter activity and the repressive effect of PHD2 co-expression was 
preserved at reduced oxygen concentration (Figure 4e, right panel). Note that pH3SVL was 
strongly induced by hypoxia and PHD2 reconstitution less efficiently reduced pH3SVL 
reporter activity under hypoxic than normoxic conditions. In conclusion, these data are all 
consistent with the notion that PHD2 represses amphiregulin transcription in a hydroxylase-
independent manner.  
 Cyclic AMP response element (CRE) binding protein (CREB)-dependent regulation of 
amphiregulin gene expression has been reported in intestinal epithelial cells and a functional 
CRE has been identified in the human amphiregulin promoter (Lee et al., 1999; O'Reilly et 
al., 2006; Plowman et al., 1990). To delineate the function of CREB in PHD2-dependent 
pAREG regulation, we co-transfected shPHD2 MCF-7 cells with wild-type or mutant CRE 
pAREG reporter plasmids together with active or mutant PHD2. While pAREG reporter 
activity was reduced upon CRE site mutation, the wild-type and mutant PHD2 repressive 
effect were preserved (Figure 4f, left panel). The HIF-dependent reporter plasmid pH3SVL 
was again used as control (Figure 4f, right panel).  
 Whereas functional NF-κB binding sites in the angiogenin as well as IL-8 promoters 
have been reported to be required for tumor necrosis factor α (TNFα)-mediated induction of 
reporter gene expression (Chan et al., 2009), amphiregulin mRNA levels were neither 
induced by TNFα treatment (Supplementary Figure S9) nor suppressed by siRNA-mediated 
downregulation of the NF-κB subunit RelA (Supplementary Figure S10). These data suggest 
that the signaling pathway involved in the PHD2-dependent control of amphiregulin 
expression in mammary carcinoma cells is different from the signaling pathway reported for 
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PHD2- and NF-κB-dependent regulation of angiogenin and IL-8 in colon carcinoma cells 
(Chan et al., 2009).  
 
HIF-2α-specific regulation of amphiregulin gene expression 
Downregulation of PHD2 in MCF-7 cells resulted in a slight normoxic accumulation of both 
HIF-1α and HIF-2α protein levels (Figure 5a). Even though amphiregulin transcriptional 
regulation was independent of PHD2 hydroxylase function, we hence investigated whether 
amphiregulin expression might additionally be regulated in a HIFα isoform-specific manner. 
Therefore, stable shHIF-1α and shHIF-2α MCF-7 pool of clones were generated (Figure 5b, 
left panel) and analyzed for amphiregulin gene expression by RT-qPCR (Figure 5b, right 
panel). Compared to parental cells, transcript levels of amphiregulin were upregulated in 
shHIF-1α and decreased in shHIF-2α MCF-7 cells, indicating that HIF-2α is mainly 
responsible for the regulation of amphiregulin gene expression. As evidenced by immunoblot 
analysis (Figure 5b, left panel), increased amphiregulin mRNA levels in shHIF-1α cells might 
probably be due to higher HIF-2α levels in these cells. Conversely, overexpression of HIF-2α 
in parental MCF-7 cells increased amphiregulin promoter-dependent reporter gene activity, 
whereas exogenous expression of HIF-1α had no effect (Figure 5c, left panel). A PHD2 
promoter-driven, i.e. HIF-dependent, reporter plasmid was used to control for efficient HIF-
1α and HIF-2α expression (Figure 5c, right panel). 
To analyze the function of HIF-2 in amphiregulin promoter regulation, we used again 
the pAREG reporter constructs depicted in Figure 4d and co-transfected them into MCF-7 
shHIF2α cells together with either HIF-2α or an empty expression vector. All pAREG 
reporter plasmids were induced by exogenous HIF-2α expression, irrespective of the presence 
of the putative HBS (Figure 5d). The promoter-less reporter backbone pGL2 served as 
negative control.  
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 Finally, either HIF-1α or HIF-2α was downregulated in shPHD2 MCF-7 cells and 
endogenous gene expression was analysed by RT-qPCR. HIF-1α suppression upregulated 
amphiregulin mRNA levels (Figure 5e), probably indirectly due to elevated HIF-2α gene 
expression as previously observed on the protein level in stable HIF-1α knock-down cell 
pools (Figure 5b). In contrast, HIF-2α suppression downregulated amphiregulin mRNA levels 
and did not influence HIF-1α gene expression (Figure 5f). CA9 served as positive control and 
seems to be a HIF-1-specific target gene. In conclusion, these data indicate that amphiregulin 
transcription is regulated by HIF-2 independent of the putative HBS in the promoter region.  
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Discussion 
Whereas the role of HIFs in tumor formation and metastasis is well known, the function of 
regulators of HIFα stability during neoplastic growth has come into focus only recently. We 
report here that PHD2 functions as a tumor suppressor in xenografted tumors derived from 
breast carcinoma MCF-7 cells and clinical data indicate that high PHD2 protein levels are a 
positive prognostic survival factor in human mammary carcinomas. Mechanistically, 
amphiregulin contributed to PHD2 regulated in vitro tube formation and amphiregulin 
transcription was increased specifically by HIF-2 in breast carcinoma MCF-7 cells.  
 During progression of our analysis, RNA interference-mediated downregulation of 
PHD2 has recently been used to further elucidate the function of PHD2 in tumor formation. 
Wu et al. observed elevated in vivo angiogenesis of tumors derived from PHD2-silenced 
NIH3T3 cells and this phenotype was attributed to HIF-mediated increased expression of the 
pro-angiogenic vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 
(FGF-2) (Wu et al., 2008). Evidence for a tumor suppressive function of PHD2 has recently 
also been reported by Chan et al. (Chan et al., 2009). PHD2 downregulation increased 
normoxic NF-κB activity, leading to a HIF-independent elevated secretion of the pro-
angiogenic factors IL-8 and angiogenin in a colon carcinoma cell model. 
Immunohistochemical analysis of PHD2 protein levels in human breast cancer samples 
showed that 6 out of 11 patient samples had higher levels of PHD2 in normal tissue than in 
matched tumor samples (Chan et al., 2009). Our analysis of ten years survival rates from 281 
clinical mammary carcinoma samples revealed significantly enhanced survival times of 
patients having tumors with high PHD2 levels, supporting the proposed tumor suppressing 
role of PHD2. While high PHD2 transcript levels have been reported in estrogen receptor 
(ER)-negative and HER2-negative breast carcinoma (Zhang et al., 2009), we found a 
significant association of low PHD2 levels with a postmenopausal state but not with tumor 
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grades, ER, progesteron receptor (PR) or HER2. Clinico-pathological data from our cohort 
were collected before the broad introduction of aromatase inhibitors for postmenopausal 
women, but association of PHD2 with postmenopausal state might still explained by ER 
status alteration, because PHD2 correlated with fatty acid synthase (FASN), another marker 
of postmenopausal status. In tumor angiogenesis, PHD2 levels have to be considered not only 
in cancer cells but also in stromal cells. Indeed, endothelial PHD2 levels have been reported 
to dramatically affect tumor growth by influencing intratumoral vessel development 
(Mazzone et al., 2009). In summary, accumulating evidence suggests an important regulatory 
role of PHD2 in tumor angiogenesis.  
Amphiregulin is a heparin-binding glycoprotein that has originally been isolated from 
conditioned media of human breast carcinoma MCF-7 cells and identified as epidermal 
growth factor receptor (EGFR) ligand (Shoyab et al., 1988). During development, 
amphiregulin is the most abundant EGF-like growth factor in the pubertal mammary gland 
and plays an important role in ductal morphogenesis (Luetteke et al., 1999). There is clear 
evidence for a role of amphiregulin in breast cancer initiation as well as progression 
(McBryan et al., 2008; Willmarth and Ethier, 2008). Amphiregulin is often overexpressed in 
mammary carcinoma (Qi et al., 1994) and generally higher in invasive breast carcinomas than 
in normal mammary epithelium (Panico et al., 1996).  
Importantly, amphiregulin antisense expression in a transformed human breast epithelial 
cell line that has been selected for its increased tumorigenicity in vivo, reversed the malignant 
phenotype in nude mice and led to a significant reduction in tumor mass (Ma et al., 1999). 
Moreover, tumor vascularization was markedly reduced in tumors derived from amphiregulin 
antisense expressing cells, suggesting that amphiregulin modulates angiogenesis in these 
cells. Although it remains largely unknown how amphiregulin might mechanistically 
contribute to breast cancer pathogenesis in general, regarding angiogenesis it has been shown 
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that amphiregulin antisense expression reduced the angiogenic factor TGFβ1 (Giusti et al., 
2003) and upregulated the expression of IL-8 in human airway epithelial cells (Chokki et al., 
2006). Our results showed that the in vitro tube formation potential of shPHD2 cells was 
signficantly increased compared to parental MCF-7 cells and again reduced after addition of 
neutralizing anti-amphiregulin antibodies, although elevated levels of the potent angiogenic 
factors VEGF and IL-8 remained unchanged. This suggests that amphiregulin contributes 
substantially to pro-angiogenic modulation by MCF-7 breast cancer cells.  
A few regulators of amphiregulin gene expression have been reported previously: EGF-
related growth factors auto- and cross-induce each other (Barnard et al., 1994), and 
amphiregulin transcription is induced by estrogen, probably indirectly as no estrogen-
response elements have been identified in the amphiregulin promoter region (Martinez-Lacaci 
et al., 1995). In fetal kidney differentiation, the zinc finger transcription factor Wilms Tumor 
suppressor (WT1) has been shown to regulate amphiregulin gene expression (Lee et al., 
1999), but we did not find any WT1 expression in MCF-7 cells (data not shown). Recently, 
BRCA1 has been described as transcriptional repressor of amphiregulin and loss of BRCA1 
resulted in elevated amphiregulin protein levels (Lamber et al., 2010). The role of oxygen in 
amphiregulin regulation is incompletely understood. Whereas hyperoxia induced 
amphiregulin in a model of bronchopulmonary dysplasia (Wagenaar et al., 2004), hypoxia has 
been reported to upregulate amphiregulin gene expression in a CREB-dependent manner in 
intestinal epithelial cells (O'Reilly et al., 2006).  
Our results suggest that PHD2 regulates amphiregulin on the transcriptional level, 
directly or indirectly involving HIF-2 but not HIF-1 (a schematic overview is shown in 
Supplementary Figure S11). Intriguingly, although HIF-2 clearly increased endogenous 
amphiregulin mRNA levels and exogenous amphiregulin promoter activity, cultivation of 
MCF-7 cells under hypoxic conditions did not significantly regulate endogenous 
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amphiregulin transcript levels or promoter activity. These data suggest that normoxic, basal 
HIF-2 levels are sufficient for amphiregulin gene expression which is not further induced by 
hypoxic stabilization of HIF-2α. Supporting this hypothesis, it has been shown that HIF-2 is 
slightly more abundant in normoxic and mildly hypoxic cells than HIF-1 (Wiesener et al., 
1998) and a recent report demonstrated that the HIF-2-specific target gene CITED2 was 
maximally expressed under normoxic conditions (Franovic et al., 2009). Furthermore, it has 
been shown that the vascular endothelial (VE)-cadherin gene is not regulated by hypoxic 
conditions, but the VE-cadherin promoter is nevertheless activated by HIF-2 together with the 
Ets-1 transcription factor (Le Bras et al., 2007).  
 Several groups reported on the role of PHDs in regulating in vivo angiogenesis. 
Conditional knock-out of PHD2, but not PHD1 or PHD3, resulted in increased secretion of 
VEGF and enhanced angiogenesis (Takeda et al., 2007) and application of pan-PHD 
inhibitors in rats led to HIFα stabilization and stimulated angiogenesis (Warnecke et al., 
2003). As PHD inhibitors have been developed to treat ischemic diseases, concerns might 
arise about adverse effects of these inhibitors in tumor progression. Our study demonstrates 
that PHD2 plays a critical role in tumor progression, suggesting that a combinatory treatment 
regimen of PHD inhibitors together with anti-angiogenic compounds or, if available, anti-
HIFα isoform specific inhibitors, might be required to avoid the induction of potentially 
tumor promoting signaling pathways.  
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Materials and methods 
Plasmids 
Cloning of PHD2 expression vectors and other plasmids was carried out using Gateway 
technology (Invitrogen, Basel, Switzerland) as described previously (Barth et al., 2007).  
 
Cell culture and transfections 
Human MCF-7 breast carcinoma cells were cultured in high-glucose Dulbecco’s modified 
Eagle’s medium (DMEM) (Sigma, Buchs, Switzerland) as described previously (Camenisch 
et al., 1999). HUVEC cells were kindly provided by T. F. Lüscher (Zürich, Switzerland) and 
cultured in complete endothelial basal medium (EBM-2) containing 2% FCS (Lonza, Basel, 
Switzerland). For long-term hypoxia, cells were grown in a gas-controlled glove box (InvivO2 
400, Ruskinn Technologies, Leeds, UK). Transfections were performed using 
polyethylenimine (Polysciences, Warrington, PA, USA) as described previously (Stiehl et al., 
2006).  
 
Immunoblotting 
Immunoblot analyses were performed as previously described (Balamurugan et al., 2009). 
Antibodies used were mouse monoclonal antibody (mAb) anti-HIF-1α (Transduction 
Laboratories, BD Biosciences, Allschwil, Switzerland), anti-HIF-2α (Novus Biologicals, 
LuBioScience, Lucerne, Switzerland), mAb anti-V5 (Invitrogen), mAb anti-β-actin (Sigma), 
rabbit polyclonal anti-PHD2 antibody (Novus), mAb anti-PHD3 was kindly provided by P. J. 
Ratcliffe (Oxford, UK).  
 
Reporter gene assays 
17 
Bordoli et al.  
Construction of the HIF-dependent firefly luciferase reporter gene construct pH3SVL was 
described previously (Wanner et al., 2000). The amphiregulin promoter plasmid pAREG(-
641/+120) was kindly provided by S. B. Lee (Bethesda, USA) (Lee et al., 1999). Truncations 
of this plasmid have been constructed by PCR and recombinant cloning techniques. As 
sequencing revealed point mutations in the parental plasmid, the (-120/+120) region was de 
novo cloned from MCF-7 genomic DNA. The consensus CRE site (5’-TGACGTC-3’) in 
pAREG(-120/+120), located 65 nucleotides upstream of the transcriptional start site, was 
mutated to (5’-TGAaaTC-3’) by site-directed mutagenesis. The PHD2 luciferase reporter 
plasmid pP2P(-603/+3)wt is a truncated version of the previously published human PHD2 
promoter (Metzen et al., 2005). Cells were co-transfected with 200 ng reporter plasmid and 
10 ng pRLSV40 Renilla luciferase reporter vector (Promega, Dübendorf, Switzerland) and 
luciferase reporter gene activity was determined using the dual-luciferase reporter assay 
system according to the manufacturer’s instructions (Promega).  
 
mRNA quantification 
Total cellular RNA was extracted as described previously (Barth et al., 2007). First-strand 
cDNA synthesis was performed with 1-5 μg total RNA using reverse transcriptase (RT) and 
mRNA levels were measured by real-time quantitative (q) PCR using a SybrGreen qPCR 
reagent kit (Sigma) in combination with the MX3000P light cycler (Stratagene, Amsterdam, 
The Netherlands). To verify RNA integrity and equal input levels, ribosomal protein L28 
mRNA was determined, and the data were expressed as ratios relative to L28 levels. 
 
Mice xenografts 
Estrogen-releasing pellets (0.72 mg 17β-estradiol 60-days release, Innovative Research of 
America, Sarasota, FL, USA,) were subcutaneously implanted into the neck of NMRI female 
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nude mice (Harlan Europe, The Netherlands) 5 days before subcutaneous injection of 1-2 × 
107 MCF-7 cells in 200 μl PBS. Tumors were measured using a caliper every three days. 
Animal experimentation was approved by the Veterinary Office of the Kanton Zürich 
(approval number 04/2008).  
 
Tissue specimen and TMA analysis 
For immunohistochemistry, our study included TMAs of 281 invasive breast cancer cases 
diagnosed at the Institute of Surgical Pathology (University Hospital, Zürich, Switzerland) as 
described (Theurillat et al., 2007). Tumor histology was determined according to the criteria 
of the World Health Organization (2003), while disease stage was assessed according to the 
International Union Against Cancer (UICC, 2002). Tumors were graded according to Bloom 
and Richardson, as modified by Elston and Ellis (Elston and Ellis, 1993). The clinico-
pathological characteristics of the patients/tumors are described in Supplementary Table 1. 
Patient age at the time of diagnosis ranged from 26 to 98 years with a median of 61 years 
(mean 62). For statistical analysis, only cases with clinical follow-up data were considered. 
The median observation time for overall survival was 61 months for patients still alive at the 
time of analysis. Seventy-four patients (27%) died during follow-up. Data on adjuvant therapy 
was not available. PHD2 expression was semiquantitatively scored as low or high.  
 
Statistical analysis 
Where not otherwise indicated, results are presented as mean values ± standard error of the 
mean of at least n = 3 independent experiments. P-values were obtained by unpaired t-tests (*, 
P < 0.05, **, P < 0.01, ***, P < 0.001). For statistical TMA analysis, PHD2 expression data 
were analysed in crosstables with chi square test. Survival analysis was conducted according 
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to Kaplan-Meier with log rank test and multivariate Cox regression analysis (inclusion 
model). All statistics were calculated using PASW (SPSS 18) software.  
 
Immunohistochemistry 
Dissected tumors were macroscopically evaluated, cut in half, and frozen in embedding 
medium (Tissue-Tek O.C.T. compound, Sakura, USA). Acetone-fixed cryosections (8 μm) 
were blocked with 0.5% bovine serum albumin and incubated with anti-PECAM-1 antibody 
(BD Biosciences) for 1 hour at room temperature to stain blood vessels. Tumor sections were 
further incubated with Alexa 568-conjugated goat anti-rat antibodies (Invitrogen) followed by 
nuclear staining with 4,6-diamidino-2-phenylindole and mounting in Prolong medium 
(Invitrogen). Blood vessel density, area and size were quantified using Axio Vision software 
(Carl Zeiss, Feldbach, Switzerland). TMA sections were processed using an automated 
immunohistochemistry platform (Benchmark, Ventana, Roche, Illkirch, France) with a PHD2 
polyclonal anti-PHD2 antibody at 1:100 dilution (NB100-137; Novus Biologicals).  
 
shRNA constructs and lentiviral infections 
Expression vectors encoding shRNA sequences targeting human PHD2, HIF-1α, HIF-2α and 
amphiregulin driven by the U6 promoter in a pLKO.1-puro plasmid were purchased from 
Sigma. Variants of shRNA expression plasmids bearing a hygromycin resistance marker were 
generated by replacing the original puromycin resistance cassette in pLKO.1. Viral particles 
were produced in HEK293T cells using the ViraPower lentiviral expression system according 
to the manufacturer’s instructions (Invitrogen).  
 
RNA interference 
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MCF-7 cells were transfected with 100 nM siRNA duplex oligonucleotides using 
Lipofectamine 2000 (Invitrogen). The following RNA interference sequences (Invitrogen) 
were used: control siRNA, forward 5’-GCUCCGGAGAACUACCAGAGUAUUA-3’; HIF-
2α siRNA, forward 5’-CAGGUGGAGCUAACAGGACAUAGUA-3’; RelA siRNA, forward 
5’-AUCCGGUGACGAUCGUCUGUAUCUG-3’.  
 
Proteome profiler 
Cells (1.2 × 106) were incubated for 48 hours in DMEM containing 10% FCS. Supernatants 
were harvested and treated according to manufacturer’s protocol (Human Angiogenesis Array 
kit, R&D Systems Europe, Abingdon, UK). Proteome profiler arrays were carried out in 
triplicates and data are presented as ratios relative to the positive controls.  
 
Tube formation assay 
Cells (1 × 105) were incubated for 48 hours in EBM-2 medium containing 2% FCS and 
supernatants were harvested. HUVEC cells (7.5 × 103) were resuspended in 50 μl conditioned 
medium and plated into the wells of Angiogenesis μ-slides (Ibidi, Vitaris, Baar, Switzerland) 
coated with 3 mg/ml Matrigel (BD Biosciences). Tube formation was photographed after 6 
hours. Quantification was performed either by counting the branching points, defined as a 
vessel that subdivides in at least two additional vessels, or by measuring the length of the 
tubes using Axio Vision software (Carl Zeiss).  
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Figure legends 
 
Figure 1 
PHD2 downregulation promotes tumor progression. (a) Transcript levels of PHD2, HIF-1α, 
HIF-2α and ARNT were analyzed in parental, control shRNA and shPHD2 MCF-7 cells by 
RT-qPCR. Cells were exposed to hypoxia (1% O2) for up to 72 hours. (b) Protein levels of 
HIF-1α, PHD2 and PHD3 were determined by immunoblotting. (c) Parental and shPHD2 
MCF-7 cells were subcutaneously injected into nude mice and tumor growth measured over 
60 days starting from a minimal tumor diameter of 5 mm (left panel). In vitro cell 
proliferation of parental and shPHD2 MCF-7 cells was assessed by counting cells over 10 
days (right panel). (d) Examples from mammary carcinoma TMA immunostaining for PHD2 
(left panel) and ten years survival analysis by Kaplan-Meier plotting (right panel).  
 
Figure 2 
Tumor growth is repressed by PHD2 overexpression. (a) MCF-7 shPHD2 cells were 
transfected with a V5-tagged PHD2 expression vector and PHD2 protein levels determined by 
immunoblotting. (b) Protein levels of HIF-1α and HIF-2α were determined by 
immunoblotting. (c) and (d) Parental, shPHD2 C1 and PHD2-reconstituted MCF-7 cells 
(clone #2) were subcutaneously injected into nude mice and tumor volume (c) as well as 
PHD2 mRNA levels (d) determined at the end of the experiment after 60 days.  
 
Figure 3 
Tumor angiogenesis is enhanced by PHD2 suppression and subsequent amphiregulin 
upregulation. (a) PECAM-1 staining of cryosections derived from parental and shPHD2 
MCF-7 tumors. (b) Quantification of vessel number, area and diameter. (c) HUVEC cells 
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were resuspended in supernatants of parental, shPHD2 or shAREG MCF-7 cells and plated on 
matrigel-coated slides. Tube formation was quantified by estimating the number of branching 
points and overall length of the network. (d) HUVEC cells were resuspended in supernatants 
of shPHD2 cells containing a neutralizing antibody against amphiregulin and the branching 
points were counted. 
 
Figure 4 
PHD2-dependent transcriptional regulation of amphiregulin. (a) Amphiregulin mRNA levels 
of parental, shPHD2 and PHD2-reconstituted MCF-7 cells were measured by RT-qPCR. (b) 
The amphiregulin promoter-driven firefly luciferase reporter gene construct pAREG(-
640/+120) was transfected into parental, shPHD2 and PHD2-reconstituted MCF-7 cells and 
relative luciferase activities were quantified. (c) Amphiregulin and CA9 mRNA levels were 
measured by RT-qPCR in MCF-7 cells cultured under normoxic (20% O2) or hypoxic (1% 
O2) conditions for up to 72 hours. (d) Schematic representation of the reporter gene constructs 
driven by the human AREG promoter. 5’-regulatory elements are labeled relative to the 
transcriptional start site (TSS). Two putative consensus HIF binding sites (HBS) are indicated 
in capital letters. (e) 200 ng pAREG reporter constructs as indicated were co-transfected with 
either 800 ng wild-type PHD2 or a hydroxylase-deficient PHD2 mutant (mtPHD2), and 
relative luciferase activities were quantified. The HIF-dependent reporter plasmid pH3SVL 
served as control. (f) The indicated plasmids were co-transfected as mentioned above (e).  
 
Figure 5 
Amphiregulin transcription is regulated by HIF-2. (a) Protein levels of PHD2, HIF-1α and 
HIF-2α were determined by immunoblotting in parental and shPHD2 (clone C1) MCF-7 cells 
cultured under normoxic or hypoxic conditions. (b) Nuclear HIF-1α and HIF-2α protein 
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levels were determined by immunoblotting (left panel) and amphiregulin mRNA levels were 
measured in parental, shHIF-1α and shHIF-2α MCF-7 cells (right panel). (c) MCF-7 parental 
cells were cotransfected with the amphiregulin promoter construct pAREG(-640/+120) 
together with either an empty, HIF-1α or HIF-2α expression vector. Cells were cultured 
under normoxic or hypoxic conditions for 24 hours and relative luciferase activities 
quantified. A PHD2 promoter-driven reporter plasmid was used as a control. (d) MCF-7 
shHIF-2α cells were co-transfected with 200 ng pAREG reporter construct as indicated 
together with either 800 ng HIF-2α or empty expression vector, and cultured under normoxic 
conditions. Promoterless pGL2basic served as negative control. Transcript levels of HIF-1α, 
HIF-2α, amphiregulin and CA9 were analyzed in shPHD2/shHIF-1α (e) and shPHD2/siHIF-
2α (f) MCF-7 cells by RT-qPCR.  
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Supplementary Figure S1 
PHD2 protein levels were determined in parental and shRNA control MCF-7 cells by 
immunoblotting. Cells were cultivated under hypoxic conditions (1% O2) for up to 72 hours. 
 
Supplementary Figure S2 
Cell proliferation of parental MCF-7 cells was assessed by counting cells over 11 days. Cells 
were treated with either 2 nM estradiol or 1 μM of the ER antagonist fulvestrant. DMSO was 
used as solvent control.  
 
Supplementary Figure S3 
Transcript and protein levels of PHD2 in parental, shPHD2 C1 and B1 tumors were measured 
by RT-qPCR (upper panel) and immunoblotting (lower panel), respectively.  
 
Supplementary Figure S4 
PHD2 immunohistochemistry of parental and shPHD2 C1 MCF-7 cells.  
 
Supplementary Figure S5 
Protein levels of PHD2 were determined in pool of clones of lentivirally transfected shPHD2 
and sh-control MCF-7 cells by immunoblotting. Cells were cultured under normoxic (20% 
O2) or hypoxic (1% O2) conditions for 24 hours. 
 
Supplementary Figure S6 
Membranes containing arrays of antibodies derived against human angiogenic factors were 
incubated with supernatants from parental, shPHD2 and PHD2-reconstituted MCF-7 cells. 
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Quantification of membrane data in lower panels are presented as pixel densities relative to 
the positive controls.  
 
Supplementary Figure S7 
Transcript levels of amphiregulin were measured by RT-qPCR in parental and sh 
amphiregulin MCF-7 cells. 
 
Supplementary Figure S8 
MCF-7 cells were cultured under normoxic conditions in the absence or presence of 2 mM 
DMOG for up to 240 minutes. HIF-1α and PHD2 protein levels were determined by 
immunoblotting of total cell lysates (upper panel). Transcript levels of amphiregulin, PHD2 
and CA9 were determined by RT-qPCR (lower panel).  
 
Supplementary Figure S9 
Amphiregulin and TNFα mRNA levels were measured by RT-qPCR in parental MCF-7 cells 
treated without or with 20 ng/ml TNFα for the time periods indicated.  
 
Supplementary Figure S10 
Transcript levels of RelA, amphiregulin, IκBα, TNFα and CA9 were analyzed in shPHD2 
MCF-7 cells without or with (hatched columns) siRelA by RT-qPCR.  
 
Supplementary Figure S11 
Schematic summary of PHD2- and HIF-2α-dependent amphiregulin regulation. Besides the 
classical oxygen-dependent and 2-oxoglutarate (2-OG)-dependent signaling pathways, 
2 
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regulating e.g. VEGF, PHD2 might have additional functions as controling amphiregulin 
transcription indirectly or directly involving HIF-2α and other cellular factors.  
 
Supplementary Table 1 
Clinico-pathological parameters of invasive breast cancer cases and relation to PHD2 
expression.  
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Supplementary Table 1    
     
Characteristic Number of cases (%) 
PHD2 
low 
PHD2 
high 
P-Value 
  273 (100%) 82 191   
< 60 years 119 (43.6%) 32 87 0.320# 
>= 60 years 154 (56.4%) 50 104   
Pre-menopausal 55 (20.1%) 9 46 0.013# 
Post-
menopausal 
218 (79.9%) 73 145   
Invasive ductal 221 (81.0%) 65 157 0.563* 
Invasive lobular 39 (14.3%) 12 27  
NOS 18 (4.7%) 6 7   
pT1 92 (33.7%) 27 65 0.866# 
pT2 122 (44.7%) 39 83  
pT3 15 (5.5%) 3 12  
pT4 44 (16.1%) 13 31   
pN0 103 (44.0%) 28 75 0.486# 
pN1 106 (45.3%) 33 73  
pN2 17 (7.3%) 5 12  
pN3 8 (3.4%) 3 5   
G1 49 (17.9%) 18 31 0.329# 
G2 138 (50.5%) 40 98  
G3 86 (31.5%) 24 62   
ER-negative 45 (17.7%) 10 35 0.378# 
ER-positive 209 (82.3%) 60 149   
PR-negative 94 (34.7%) 28 66 0.979# 
PR-positive 177 (65.3%) 53 124   
HER2 0, 1+, 2+ 236 (90.4%) 74 162 0.111# 
HER2 3+ 25 (9.6%) 4 21   
#Chi-Square for trends, *Pearson Chi-
Square    
 
